TCR2 Therapeutics  logo
TCR2 Therapeutics TCRR

Quarterly report 2023-Q1
added 05-11-2023

report update icon

TCR2 Therapeutics Market Cap 2011-2026 | TCRR

As of April 08, 2026 TCR2 Therapeutics has a market cap of $ 58.1 M


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap TCR2 Therapeutics

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
57.9 M 127 M 781 M 316 M - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
781 M 57.9 M 320 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
315 M - 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
76.4 M - - $ 86.2 M usaUSA
Amgen Amgen
AMGN
198 B $ 350.12 2.98 % $ 188 B usaUSA
AlloVir AlloVir
ALVR
13.1 M - 4.14 % $ 49.1 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
4.31 B $ 12.68 2.92 % $ 3.97 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
22.1 M - - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
541 M - - $ 8.42 M usaUSA
argenx SE argenx SE
ARGX
13.8 B $ 781.8 2.14 % $ 25 B niderlandNiderland
I-Mab I-Mab
IMAB
127 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
33.6 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
168 B - 2.54 % $ 160 B franceFrance
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
3.44 B $ 24.48 5.18 % $ 3.11 B usaUSA
Biophytis SA Biophytis SA
BPTS
549 M - -13.47 % $ 169 M franceFrance
AVROBIO AVROBIO
AVRO
56.3 M - 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.72 M - - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
81.2 B - - $ 96.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
79 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
28.9 M - -1.52 % $ 24.7 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
322 M $ 1.5 9.93 % $ 399 M britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
253 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
895 M $ 3.9 3.72 % $ 9.38 B australiaAustralia
BioNTech SE BioNTech SE
BNTX
62.9 B $ 91.86 2.5 % $ 27.2 B germanyGermany
CymaBay Therapeutics CymaBay Therapeutics
CBAY
3.43 B - - $ 3.45 B usaUSA
Advaxis Advaxis
ADXS
1.87 M - -9.65 % $ 45.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
15.8 M $ 2.68 4.28 % $ 16.8 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
2.09 B $ 4.53 -0.22 % $ 742 M britainBritain
Avid Bioservices Avid Bioservices
CDMO
423 M - - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
148 M - - $ 1.41 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
2.83 B - - - russiaRussia
Cabaletta Bio Cabaletta Bio
CABA
283 M $ 3.05 -0.65 % $ 306 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
3.16 B $ 3.1 2.31 % $ 6.75 B israelIsrael
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
160 M - - $ 169 M usaUSA
Cerus Corporation Cerus Corporation
CERS
496 M $ 1.92 4.08 % $ 366 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
41.4 M - 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
52.7 M - - $ 231 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
14.1 K - -10.17 % $ 12.2 K usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
103 M - - $ 401 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
724 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
32.8 M - - $ 26.5 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
551 M - - $ 1.2 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
19.6 M - 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
2.32 M - -45.71 % $ 1.2 M canadaCanada
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
109 K - -4.36 % $ 27 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
7.49 M $ 2.81 2.18 % $ 7.33 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
1.2 B - - $ 2.18 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
3.25 B - - $ 3.67 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
1.73 B - - $ 2.02 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
3.53 B - - $ 867 M germanyGermany
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
6.55 M $ 3.43 -1.43 % $ 8.64 M usaUSA